These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35298050)

  • 21. Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center.
    Ríos-Viñuela E; Álvarez P; Lavernia J; Serra-Guillén C; Requena C; Bernia E; Diago A; Llombart B; Sanmartín O
    Actas Dermosifiliogr; 2022 Jun; 113(6):T610-T615. PubMed ID: 35525283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center.
    Ríos-Viñuela E; Álvarez P; Lavernia J; Serra-Guillén C; Requena C; Bernia E; Diago A; Llombart B; Sanmartín O
    Actas Dermosifiliogr; 2022 Jun; 113(6):610-615. PubMed ID: 35431057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unresectable auricular squamous cell carcinoma with locoregional metastasis: use of cemiplimab in an immunosuppressed patient.
    França TF; Gontijo JRV; Junior EFV; Lima EM
    An Bras Dermatol; 2024; 99(1):158-160. PubMed ID: 37652819
    [No Abstract]   [Full Text] [Related]  

  • 24. Cemiplimab for Orbital Squamous Cell Carcinoma in 11 Cases.
    Steren B; Burtness B; Bhatia A; Demirci H; Shinder R; Yoo D; Tse B; Pointdujour-Lim R
    Ophthalmic Plast Reconstr Surg; 2022 Sep-Oct 01; 38(5):496-502. PubMed ID: 35502804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cemiplimab in advanced cutaneous squamous cell carcinoma.
    Naik PP
    Dermatol Ther; 2021 Nov; 34(6):e15184. PubMed ID: 34716727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel.
    Lebas E; Marchal N; Rorive A; Nikkels AF
    Expert Rev Anticancer Ther; 2021 Apr; 21(4):355-363. PubMed ID: 33554680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real-world retrospective study from Spain and systematic review of the published data.
    Cañueto J; Muñoz-Couselo E; Cardona-Machado C; Becerril-Andrés S; Martín-Vallejo J; Serra-Guillén C; Soria A; Serrano-Domingo JJ; Ortiz-Velez C; Lostes J; García-Castaño A; Puig S; Fernández de Misa R; Medina J; Aguado C; Ayala de Miguel P; Navarro-Navarro I; Masferrer E; Delgado M; Bellido-Hernández L; Sanmartin O
    J Eur Acad Dermatol Venereol; 2024 Aug; 38(8):e666-e670. PubMed ID: 38308557
    [No Abstract]   [Full Text] [Related]  

  • 28. Dichotomic response patterns to PD-1 blockade with cemiplimab in a patient with multiple squamous cell carcinomas.
    Bazzacco G; Zelin E; Toffoli L; Conforti C; di Meo N; Fedele D; Zalaudek I
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):e547-e549. PubMed ID: 36305888
    [No Abstract]   [Full Text] [Related]  

  • 29. Safety of cemiplimab for advanced cutaneous squamous cell carcinoma in a patient with p-ANCA-associated vasculitis.
    Pham JP; Sivasubramaniam V; Gallagher R; Forstner D; Wong M; Liu J
    J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):e363-e365. PubMed ID: 36226470
    [No Abstract]   [Full Text] [Related]  

  • 30. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis.
    Rischin D; Khushalani NI; Schmults CD; Guminski A; Chang ALS; Lewis KD; Lim AM; Hernandez-Aya L; Hughes BGM; Schadendorf D; Hauschild A; Thai AA; Stankevich E; Booth J; Yoo SY; Li S; Chen Z; Okoye E; Chen CI; Mastey V; Sasane M; Lowy I; Fury MG; Migden MR
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34413166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies.
    Yang F; Paccaly AJ; Rippley RK; Davis JD; DiCioccio AT
    J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):479-494. PubMed ID: 33728546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral ulcers and sarcoid-like reaction in lymph nodes after cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma: a case report.
    Ferreira MH; Bezinelli LM; Eduardo FP; Gobbi MF; Corrêa L; Schvartsman G
    Einstein (Sao Paulo); 2022; 20():eRC6367. PubMed ID: 35303053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
    Migden MR; Rischin D; Schmults CD; Guminski A; Hauschild A; Lewis KD; Chung CH; Hernandez-Aya L; Lim AM; Chang ALS; Rabinowits G; Thai AA; Dunn LA; Hughes BGM; Khushalani NI; Modi B; Schadendorf D; Gao B; Seebach F; Li S; Li J; Mathias M; Booth J; Mohan K; Stankevich E; Babiker HM; Brana I; Gil-Martin M; Homsi J; Johnson ML; Moreno V; Niu J; Owonikoko TK; Papadopoulos KP; Yancopoulos GD; Lowy I; Fury MG
    N Engl J Med; 2018 Jul; 379(4):341-351. PubMed ID: 29863979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cemiplimab and ruxolitinib in concomitant cutaneous squamous cell carcinoma and myelofibrosis.
    Di Raimondo C; Rao L; Lozzi F; Lombardo P; Silvaggio D; Vellucci L; Tofani L; Campione E; Bianchi L
    Dermatol Ther; 2022 May; 35(5):e15421. PubMed ID: 35249252
    [No Abstract]   [Full Text] [Related]  

  • 35. Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System.
    Liu Y; Fitzgerald B; Perry E; Pathak A; Chao HH
    J Investig Med High Impact Case Rep; 2019; 7():2324709619850216. PubMed ID: 31132886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma.
    Valentin J; Gérard E; Ferte T; Prey S; Dousset L; Dutriaux C; Beylot-Barry M; Pham-Ledard A
    J Geriatr Oncol; 2021 Sep; 12(7):1110-1113. PubMed ID: 33736973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infrequent liver injury from cemiplimab in patients with advanced cutaneous squamous cell carcinoma.
    Swanson L; Kassab I; Tsung I; Worden FP; Fontana RJ
    Immunotherapy; 2022 Apr; 14(6):409-418. PubMed ID: 35232282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review.
    Banini M; Salvestrini V; Vultaggio A; Perlato M; Mecheri V; Cerbai C; Scotti V; Matucci A; Mangoni M; Livi L; Bonomo P
    Curr Oncol; 2023 Jul; 30(7):6699-6707. PubMed ID: 37504351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.
    Ahmed SR; Petersen E; Patel R; Migden MR
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):947-951. PubMed ID: 31524530
    [No Abstract]   [Full Text] [Related]  

  • 40. Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature.
    Deinlein T; Lax SF; Schwarz T; Giuffrida R; Schmid-Zalaudek K; Zalaudek I
    Eur J Cancer; 2017 Sep; 83():99-102. PubMed ID: 28734147
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.